AgingResearch.NewsJoin free

ANTI-IGFBP7 antibody

ANTI-IGFBP7 antibody has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 1, 2022: “Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure”.

Intervention

1 paper studies it1 findingUpdated

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: CIHR Skin Research Training Centre and 4 more
  • 1 of 1 finding with company ties
  • Animals1

What did studies of ANTI-IGFBP7 antibody find?

1

Studies of ANTI-IGFBP7 antibody measured 1 outcome; the most studied are heart failure (1 study).

Heart failure

downin mice1

1 study

  1. ANTI-IGFBP7 antibody decreases heart failure in mice.

    “antibody-mediated IGFBP7 neutralization in vivo reversed IGFBP7-induced suppression of FOXO3a, restored DNA repair and ROS detoxification signals and attenuated pressure-overload-induced HF in mice.”

    Animalspressure-overload-induced heart failureheart

    Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure

    Nature cardiovascular research

More on Heart failure

Latest

Related